Occupational Asthma Reference
    
    
 
  | 
    
    Miller ME, Lummus ZL, Bernstein DI,
    Occupational asthma caused by FD&C blue dye no. 2,
    Allergy Asthma Proc,
    1996;17:31-34,
   | 
 
 
 | 
  
  | 
 
 
	Keywords: USA, indigotine, dye, case report, ch, food, nc, Male, who, cough, non-occupational, IgE, IgA, IgM, IgG, ets, alveolitis, X, FEV1, asthma
 	
	
 
	
 
	
					Known Authors
					
  	
 If you would like to become a known author and have your picture displayed along with your papers then please get in touch from the contact page. Known authors can choose to receive emails when their papers receive comments.
 
 
 
					Abstract
 
					
					
					We report the case of a 55-year-old male who experienced cough, dyspnea, wheezing, and nasal congestion immediately upon exposure to FD&C Blue Dye No. 2 (Indigotine) at work. The patient had worked for 10 years mixing and grinding powdered synthetic red, yellow, and blue dyes for use in foods; symptoms had occurred for 2 years and only with exposure to Indigotine (C16H8N2Na2O8S2), a free flowing blue powder. Prick testing to Indigotine (20 mg/mL) was negative. ELISA failed to detect specific IgE, IgA, IgM, or IgG to Indigotine-HSA conjugates. Bronchial challenge was done according to the method of Pepys et al. beginning with 4 x 10(-4) lactose dilution of Indigotine powder. After 5 minutes of exposure to 4 gm Indigotine/100 gm lactose, the patient developed dyspnea and audible wheezing. At 20 minutes postexposure, there was a 20% decline in FEV1 from prechallenge baseline; no late phase response was observed. A second bronchial challenge with sodium sulfate, the major nondye product additive was negative. To our knowledge, this is the first documented case of occupational asthma due to FD&C Blue Dye No. 2. The pathogenesis is uncertain but does not appear to be IgE mediated
					
 		
					Full Text
 
	
     Full text of this reference not available
			
			
			
		
			Please Log In or Register to add the full text to this reference
			
	      
 
 
 				
				
			
				Comments
				
			 
 
 
 
 
 
 
	
 Please sign in or register to add your thoughts.